New Adjuvant Option for BRAF Melanoma

Combined targeting with BRAF and MEK inhibitors will soon move into the adjuvant setting for treating BRAF-V300-positive stage III melanoma, say experts.
Medscape Medical News

http://ift.tt/2h17OQt